{"id":"4e4166a4a535","type":"article","url":"https://hartvaat.nl/2016/12/06/comorbiditeiten-bij-hartfalen-hypertensie-obesitas-diabetes-hyperlipidemie-en-me/","title":"Comorbiditeiten bij hartfalen: hypertensie, obesitas, diabetes, hyperlipidemie en metabool syndroom","title_en":"Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","bisoprolol","cardio-renaal-metabool","diabetes-en-hart","dyslipidemie","obesitas","select-trial","vrouwen"],"journal":"Circulation","doi":"10.1161/CIR.0000000000000450","source_url":"https://doi.org/10.1161/CIR.0000000000000450","authors":["Biykem Bozkurt","David Aguilar","Anita Deswal","Sandra B Dunbar","Gary S Francis","Tamara Horwich","Mariell Jessup","Mikhail Kosiborod","Allison M Pritchett","Kumudha Ramasubbu","Clive Rosendorff","Clyde Yancy"],"significance":7,"published":"2016-12-06","source_date":"2016-12-06","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This AHA scientific statement addressed the contributory role and management of comorbidities (hypertension, obesity, diabetes, dyslipidemia, and sleep apnea) in heart failure, providing an integrated framework for comorbidity-driven heart failure prevention and treatment.","created":"2026-07-03T10:26:26Z","updated":"2026-07-03T18:38:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"AHA scientific statement over de bijdrage en het management van comorbiditeiten bij hartfalen. Integrale benadering van het cardiometabole risicoprofiel bij HF-patiënten.","abstract_original":""}